Ogen 1.25
Low Testosterone, hypoestrogenism, moderate Vulvovaginal atrophy + 7 more
Treatment
13 FDA approvals
20 Active Studies for Ogen 1.25
Treatment for
Low Testosterone
What is Ogen 1.25
Estrone sulfate
The Generic name of this drug
Treatment Summary
Estrone sulfate (as estropipate) is a form of estrogen hormone replacement therapy that can be used to treat menopause symptoms, certain types of infertility, underdevelopment of female sexual characteristics, vaginal atrophy, certain types of breast cancer (especially in men and postmenopausal women), prostate cancer, and osteoporosis.
Ogen
is the brand name
Ogen 1.25 Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ogen
Estrone sulfate
1977
21
Approved as Treatment by the FDA
Estrone sulfate, also known as Ogen, is approved by the FDA for 13 uses including Hypogonadism and Postmenopausal Osteoporosis .
Hypogonadism
Postmenopausal Osteoporosis
Premature Ovarian Failure (POF)
Hot flashes
Premature Menopause
moderate Menopausal Vasomotor Symptoms
moderate Vulvovaginal atrophy
Low Testosterone
hypoestrogenism
Osteoporosis, Postmenopausal
Menopause
female castration
severe menopausal vulvovaginal atrophy
Effectiveness
How Ogen 1.25 Affects Patients
Estropipate is a type of estrogen, which is a hormone naturally produced by the body. Estropipate works by attaching to receptors that respond to estrogen in the body and helps to regulate the hormones LH and FSH. This can help to lower their levels in postmenopausal women.
How Ogen 1.25 works in the body
Estradiol is a hormone that acts on female organs, breasts, and other parts of the body. When it enters a cell, it binds to a receptor and enters the nucleus. This triggers the production of proteins that express the effects of estradiol on the cell. Estrogens also increase the production of certain proteins in the liver and decrease FSH production in the pituitary gland.
When to interrupt dosage
The proposed dosage of Ogen 1.25 is contingent upon the diagnosed circumstance, including Menopause, Menopause and hypoestrogenism. The quantity of dosage varies, in accordance with the delivery strategy (e.g. Oral or Tablet, coated) mentioned in the table below.
Condition
Dosage
Administration
female castration
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Menopause
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
severe menopausal vulvovaginal atrophy
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Low Testosterone
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
hypoestrogenism
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
moderate Vulvovaginal atrophy
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Osteoporosis, Postmenopausal
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Premature Menopause
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
moderate Menopausal Vasomotor Symptoms
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Hot flashes
0.75 mg, , 1.5 mg, 3.0 mg, 0.625 mg, 1.25 mg, 1.5 mg/mL, 0.0015 mg/mg, 6.0 mg
Oral, Tablet, Tablet - Oral, , Tablet, film coated, Tablet, film coated - Oral, Cream, Vaginal, Cream - Vaginal, Tablet, coated - Oral, Tablet, coated
Warnings
There are 20 known major drug interactions with Ogen 1.25.
Common Ogen 1.25 Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Estrone sulfate.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Estrone sulfate.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Estrone sulfate.
Anagrelide
Major
The metabolism of Anagrelide can be decreased when combined with Estrone sulfate.
Anastrozole
Major
The therapeutic efficacy of Anastrozole can be decreased when used in combination with Estrone sulfate.
Ogen 1.25 Novel Uses: Which Conditions Have a Clinical Trial Featuring Ogen 1.25?
39 active clinical trials are presently investigating the potential of Ogen 1.25 in alleviating Low Testosterone, hypoestrogenism and moderate Menopausal Vasomotor Symptoms.
Condition
Clinical Trials
Trial Phases
female castration
0 Actively Recruiting
hypoestrogenism
1 Actively Recruiting
Phase 4
moderate Menopausal Vasomotor Symptoms
0 Actively Recruiting
moderate Vulvovaginal atrophy
0 Actively Recruiting
Premature Menopause
0 Actively Recruiting
Osteoporosis, Postmenopausal
0 Actively Recruiting
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1
Menopause
0 Actively Recruiting
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
severe menopausal vulvovaginal atrophy
0 Actively Recruiting
Ogen 1.25 Reviews: What are patients saying about Ogen 1.25?
5
Patient Review
4/12/2012
Ogen 1.25 for "Change of Life" Signs
5
Patient Review
7/16/2010
Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries
5
Patient Review
6/10/2010
Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries
5
Patient Review
5/21/2009
Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries
2
Patient Review
12/15/2009
Ogen 1.25 for Low Estrogen After Operation to Remove Ovaries
Patient Q&A Section about ogen 1.25
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What does OGEN do?
"Ogen (estropipate) tablets are a prescription medication used to treat the symptoms of menopause, ovarian failure, and the prevention of osteoporosis. Ogen may be used alone or with other medications and belongs to a class of drugs called estrogen derivatives. The safety and effectiveness of Ogen in children is not yet known."
Answered by AI
What does Premarin do to your body?
"Premarin is a type of hormone replacement therapy that helps to relieve the discomfort that many women feel during and after menopause. These symptoms include hot flashes, sweating, and vaginal dryness."
Answered by AI
What is OGEN made of?
"10, FD&C Blue No 1 and FD&C Red No. 3; OGEN. 750 (red tablet): FD&C Red No. 40, D&C Red 33,Yellow No. 6 and Red No. 3.
OGEN also contains colloidal silicon dioxide, dibasic potassium phosphate, hydrogenated vegetable oil wax, hydroxypropyl cellulose, lactose, magnesium stearate, microcrystalline cellulose, sodium starch glycolate and tromethamine. The color ingredients for the yellow tablet are: D&C Yellow No. 10, FD&C Blue No 1 and FD&C Red No. 3; The color ingredients for the red tablet are: FD&C Red No. 40, D&C Red 33,Yellow No. 6 and Red No. 3."
Answered by AI
Can you crush extended release tablets?
"There are some newer slow-release tablet formulations available that can be divided or halved."
Answered by AI